Form 4: Guided Therapeutics Insider John E. Imhoff Reports Significant Changes in Beneficial Ownership

John E. Imhoff, a director and 10% owner of Guided Therapeutics, reports a series of transactions involving preferred and common stock, including conversions, purchases, and exchanges.

Summary

• On March 6, 2025, John E. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock.
• Also on March 6, 2025, Imhoff converted Series C2 preferred stock, receiving 4,801,500 common shares for 2,400.75 Series C2 preferred shares.
• On March 7, 2025, Imhoff purchased 286 shares of Series C preferred stock for $112,934.50, which were later converted to 2,258,690 common shares on March 11, 2025.
• On March 18, 2025, Guided Therapeutics entered into a Securities Purchase Agreement with Imhoff, selling 1,000,000 units, each consisting of one share of common stock and one warrant, for $100,000.
• In connection with the March Purchase Agreement, Imhoff exchanged a $25,000 note payable and accrued interest of $1,307 for 263,069 units.
• On April 10, 2025, 6,365 shares were issued for payment of accrued dividends on Imhoff's Series F preferred stock.
• Following these transactions, Imhoff directly owns 17,992,380 shares of common stock and 1,263,069 warrants.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The transactions themselves could be interpreted as either positive (insider confidence) or negative (dilution), but the filing itself is simply a disclosure.

Positives

• Insider participation in the Securities Purchase Agreement could be seen as a positive signal.

Risks

• The transactions involve the issuance of a significant number of new shares, which could potentially dilute existing shareholders.
• The company's reliance on insider funding may indicate difficulty in attracting external investment.

Future Outlook

The document does not contain explicit forward-looking statements, but the transactions suggest continued reliance on insider funding.

Industry Context

Form 4 filings are standard disclosures for publicly traded companies and provide transparency into insider transactions. The transactions themselves may be related to the company's overall financing strategy and capital structure.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for all publicly traded companies in the US, ensuring transparency of insider transactions.
• The specifics of the transactions (stock conversions, warrant issuances) are company-specific and depend on their capital structure and financing needs.
• Comparing Guided Therapeutics' insider activity to companies like Exact Sciences (EXAS) or Hologic (HOLX) would require analyzing their respective Form 4 filings and overall financial strategies.

Related Party Transactions

• The Securities Purchase Agreement and exchange agreement with Dr. Imhoff, a director and 10% owner, constitute related party transactions.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The transactions could impact the company's financial stability and future fundraising efforts.

Key Dates

Keywords

beneficial ownership, Form 4, insider trading, John E. Imhoff, Guided Therapeutics, GTHP, common stock, preferred stock, warrants, conversion, exchange agreement, securities purchase agreement